[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arthritis-hip\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arthritis-hip":57},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100499804","developing-an-opioid-taper-intervention-before-total-joint-arthroplasty-100499804",false,"NCT05788016","Developing an Opioid Taper Intervention Before Total Joint Arthroplasty","Developing and Testing an Opioid Taper Intervention Before Total Knee Arthroplasty: Phase 2 Intervention Development","Inclusion Criteria:\n\n* decided to pursue primary, unilateral total knee or hip arthroplasty with planned surgery date in 4-8 weeks\n* currently taking between 20 and 90 MME of oral opioids, and that dose has been stable for at least 3 months\n* have a reliable telephone number for contact\n* speaks English\n\nExclusion Criteria:\n\n* Taking opioid medications that include:\n\n  * Buprenorphine\n  * Methadone\n  * Long-acting formulations of opioid pain medications (e.g., extended-release oxycodone and extended-release morphine)\n  * Transdermal formations of opioid pain medications (e.g., fentanyl patches)","ALL","18 Years",{"count":19,"type":20},45,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are:\n\n* Is the intervention feasible and acceptable to patients?\n* Does the intervention result in a decrease in opioid dose during the preoperative period?\n\nParticipants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.",[26,27,28],"Arthritis Knee","Arthritis Hip","Chronic Pain",[30],"Opioids","RECRUITING","2026-05-27",{"date":34,"type":35},"2026-05-29","ACTUAL",{"date":37,"type":35},"2024-01-10",{"date":39,"type":20},"2027-07-01",{"name":41,"class":42},"University of Alabama at Birmingham","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100575701","clinical-and-radiological-outcomes-of-the-romax-hip-resurfacing-system-100575701","NCT06775704","Clinical and Radiological Outcomes of the ROMAX Hip Resurfacing System","Résultats Cliniques et Radiologiques du Dispositif de resurfaçage de Hanche ROMAXTM Medacta","Inclusion Criteria:\n\n* Patients eligible for hip resurfacing, suitable for the implantation of a Medacta ROMAX hip resurfacing system according to the manufacturer's defined indication for use.\n* Aged between 18 and 65 years at the time of surgery.\n* Ability and willingness to provide written informed consent for participation.\n\nExclusion Criteria:\n\n* Active infection\n* BMI \\> 40\n* Mental illness, when the known pathology is likely to compromise the patient's ability to consent, affect the patient's assessment of their progress, or complete follow-up appointments and exams.\n* Significantly deformed anatomy (at the surgeon's discretion)\n* Osteomalacia where the fixation of an uncemented implant is contraindicated\n* Active rheumatoid arthritis\n* Osteoporosis\n* Metabolic disorders likely to impair bone formation and for which the fixation of an uncemented implant is contraindicated\n* Muscle atrophy or neuromuscular disease\n* Known allergy or hypersensitivity to the implant material\n* Any patient who cannot or does not wish to give informed consent to participate in the study\n* Patients whose chances of regaining independent mobility would be compromised by known concomitant medical issues.","65 Years",{"count":53,"type":20},150,"OBSERVATIONAL","The goal of this observational study is to collect clinical and radiological data to monitor the safety and performance of the ROMAX hip resurfacing system. The main parameter that will be measured is the rate of revisions at 10 years.",[57,58],"Arthritis (Hip)","Hip Dysplasia, Congenital",[60],"resurfacing","2025-09-22",{"date":63,"type":35},"2025-09-25",{"date":65,"type":35},"2025-07-14",{"date":67,"type":20},"2037-04-01",{"name":69,"class":70},"Medacta International SA","INDUSTRY"]